Navigation Links
Researchers help in search for new ways to image, therapeutically target melanoma
Date:11/3/2011

TAMPA, Fla. (Nov. 3, 2011) Because the incidence of malignant melanoma is rising faster than any other cancer in the U.S., researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Tampa-based Intezyne Technologies, Inc., Western Carolina University and the University of Arizona are working overtime to develop new technologies to aid in both malignant melanoma diagnosis and therapy. A tool of great promise comes from the world of nanomedicine where tiny drug delivery systems are measured in the billionths of meters and are being designed to deliver targeted therapies.

Which therapies are appropriate to be loaded into nano-sized vehicles to attach to the right receptors for targeting purposes is an issue.

"Melanoma progression is associated with altered expression of cell surface proteins, including adhesion proteins and receptors," said study co-author David L. Morse, Ph.D., whose work at Moffitt includes experimental therapeutics and diagnostic imaging. "Eighty percent of malignant melanomas express high levels of the MC1R receptor, one of a family of five receptors."

Their study, published in a recent issue of the Journal of Medicinal Chemistry, tested the family of receptors, including MC1R, to find out which receptors would respond best when the right ligand was loaded into a nano-sized spherical delivery device resembling a Koosh Ball called a "micelle."

According to study co-author Robert J. Gillies, Ph.D., director of Molecular and Functional Imaging and vice chair of Radiology Research at Moffitt, MC1R has been in the past investigated as a target for selective imaging and for potential therapeutic agents and is known to play a role in skin pigmentation and hair color. The search for the right "ligand" (a substance that forms a complex with a biomolecule) for use in targeting the right receptor, is ongoing.

"The development of ligands that can be attached to micelles and/or nanoparticles to target cancer cells relative to healthy organs is a subject of great research and great potential," said Gilles.

However, failures in this effort can emerge when attachments lose affinity, when poor stability results in collapse before the nano-sized vehicle gets to the vicinity of the tumor, or when the nanoparticle size is too big to escape the body's vascular system. Each issue needs to be addressed, said Gillies.

In this study, Gilles and Morse and colleagues tested one ligand that was found to have "high affinity and selectivity" for MC1R. That ligand was subsequently modified for attachment to a polymer micelle. Noting the three hurdles to be overcome ligand affinity, nanoparticle stability and right nanoparticle size the authors concluded that their chosen ligand "remained selective after attachment" and that the increased binding affinity of the ligand to MC1R demonstrated the stability of the system.

"We are also confident that our micelles are of sufficient size to escape the vasculature, and studies in mice are underway to evaluate the selectivity and stability of this targeted micelle system," concluded Morse.

The Moffitt researchers and their colleagues also feel that this development is a step in the right direction toward more effective imaging of malignant melanoma as well as the development of better targeted therapies for individualized treatment of the disease using nano-sized drug delivery systems.


'/>"/>

Contact: Ferdie De Vega
Ferdinand.DeVega@moffitt.org
813-745-7858
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Univesity of Notre Dame researchers form new partnership to help trauma patients
2. Ohio State researchers design a viral vector to treat a genetic form of blindness
3. Researchers reveal potential treatment for sickle cell disease
4. Senior citizens as co-researchers to improve urban planning
5. Plant researchers locate transporter used for nicotine metabolism
6. Live-action films of worm sperm help researchers track critical fertility enzymes
7. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
8. Researchers identify potential risk factors for severe altitude sickness
9. Moffitt Cancer Center researchers find more clues to causes of breast cancer
10. Georgetown researchers examine 21-year series of nipple sparing mastectomy cases and find no cancers
11. Medical researchers ID potential new drug target that could stop debilitating effects of MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... Wooden and plastic balance boards have been around since at least ... Kumo Board is the first and only balance board to use a patent-pending design ... rigid at the same time as well as skill-level adjustable for all ages and abilities. ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate ... about the benefits of making new water infrastructure a number one priority. “As we ... we expect water infrastructure to become a top priority of our new political change ...
(Date:1/23/2017)... ... 2017 , ... Zachary Cattell, President of the Indiana Health ... expert at the 2017 Sector Summit hosted by Ivy Tech Community College on ... Dick, will feature an employer and an association representative from five of Indiana’s ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... applications. However, choosing the right method is paramount to success. Selecting an inappropriate ... in situations where multiple persons use the same equipment. Rare or expensive substances ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... "ProRandom is a set of camera tools ... create dynamic looks in Final Cut Pro X," said Christina Austin - CEO of Pixel ... to two layers of text with video footage. ProRandom works by using a virtual ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... The American Pharmacists Association (APhA) is excited ... Medically Underserved Areas Enhancement Act (H.R. 592) ... was previously introduced in the 114 th session ... through pharmacists and their patient care services. ... (R-KY), G.K. Butterfield (D-NC), Tom ...
(Date:1/23/2017)... , January 23, 2017 Ahead of ... to see how they have fared at the close: Kite Pharma ... Inc. (NASDAQ: OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... Biotechnology shares were relative laggards on Friday, January 20 th , ... our complimentary research reports on these stocks now at: ...
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries are factors ... BCC Research reveals in its new report that markets in developing ... strong growth due to rising government healthcare spending, increased levels of healthcare ... Reading ... BCC ...
Breaking Medicine Technology: